Product Name
CCDC40, siRNA
Full Product Name
CCDC40 siRNA (Human)
Product Synonym Names
KIAA1640; Coiled-coil domain-containing protein 40
Product Gene Name
CCDC40 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q4G0X9
Specificity
CCDC40 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human CCDC40 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of CCDC40 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
CCDC40 sirna
siRNA to inhibit CCDC40 expression using RNA interference
Applications Tested/Suitable for CCDC40 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for CCDC40. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001230271.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001243342.1
[Other Products]
UniProt Primary Accession #
Q4G0X9
[Other Products]
UniProt Secondary Accession #
Q6PE47; Q9HCD2; Q9NWL5; A8MTD2; C9JTI9; C9JTJ0; C9JXW1; J3QSY2[Other Products]
UniProt Related Accession #
Q4G0X9[Other Products]
Molecular Weight
52,263 Da
NCBI Official Full Name
coiled-coil domain-containing protein 40 isoform 2
NCBI Official Synonym Full Names
coiled-coil domain containing 40
NCBI Official Symbol
CCDC40 [Similar Products]
NCBI Official Synonym Symbols
CILD15; FAP172
[Similar Products]
NCBI Protein Information
coiled-coil domain-containing protein 40
UniProt Protein Name
Coiled-coil domain-containing protein 40
Protein Family
Coiled-coil domain-containing protein
UniProt Gene Name
CCDC40 [Similar Products]
UniProt Entry Name
CCD40_HUMAN
NCBI Summary for CCDC40
This gene encodes a protein that is necessary for motile cilia function. It functions in correct left-right axis formation by regulating the assembly of the inner dynein arm and the dynein regulatory complexes, which control ciliary beat. Mutations in this gene cause ciliary dyskinesia type 15, a disorder due to defects in cilia motility. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2011]
UniProt Comments for CCDC40
CCDC40: Required for assembly of dynein regulatory complex (DRC) and inner dynein arm complexes, which are responsible for ciliary beat regulation, thereby playing a central role in motility in cilia and flagella. Not required for outer dynein arm complexes assembly. Required for axonemal recruitment of CCDC39. Defects in CCDC40 are the cause of primary ciliary dyskinesia type 15 (CILD15). A disorder characterized by abnormalities of motile cilia. Respiratory infections leading to chronic inflammation and bronchiectasis are recurrent, due to defects in the respiratory cilia; reduced fertility is often observed in male patients due to abnormalities of sperm tails. Half of the patients exhibit randomization of left-right body asymmetry and situs inversus, due to dysfunction of monocilia at the embryonic node. Primary ciliary dyskinesia associated with situs inversus is referred to as Kartagener syndrome. Belongs to the CCDC40 family. 5 isoforms of the human protein are produced by alternative splicing.
Chromosomal Location of Human Ortholog: 17q25.3
Cellular Component: cytoplasm; cilium
Biological Process: heart looping; lung development
Disease: Ciliary Dyskinesia, Primary, 15
Research Articles on CCDC40
1. Lung disease was worse in those with IDA/CA/MTD ultrastructural defects, most of whom had biallelic mutations in ccdc40.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
